Literature DB >> 22050094

Perforin and granzyme B expression in oral and cutaneous lichen planus - a comparative study.

Denise Lage1, Vanessa N Pimentel, Tania C B Soares, Elemir M Souza, Konradin Metze, Maria L Cintra.   

Abstract

BACKGROUND: Although cutaneous and oral lichen planus (LP) share similar histopathological features, oral LP often follows a recalcitrant course while LP skin lesions tend to be self-limiting. Apoptosis, mediated by cytotoxic T-cells in LP, may be triggered by the release of molecules such as perforin and granzyme B. As variation in clinical behavior can reflect differences in LP immune expression, we studied the role of those cytotoxic molecules in oral and cutaneous LP.
METHODS: We analyzed 16 cases of cutaneous LP and 29 of oral LP. The sections were studied on hematoxylin and eosin, CD4, CD8, perforin and granzyme B staining.
RESULTS: The mean number of immunostained cells expressing each cytotoxic molecule was significantly higher in oral LP than in cutaneous LP. A higher number of single necrotic keratinocytes (apoptotic bodies) was found in oral LP lesions when compared to cutaneous LP. Only in oral LP lesions, a higher number of CD4-positive cells was found in active lesions when compared to regressive lesions.
CONCLUSIONS: Our results confirm increased expression of granzyme B and perforin in oral LP lesions as compared to cutaneous LP. The increased expression suggests a relationship with the clinical behavior of the disease.
Copyright © 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22050094     DOI: 10.1111/j.1600-0560.2011.01781.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  8 in total

1.  Comparison of serum lipid parameters between patients with classic cutaneous lichen planus and oral lichen planus.

Authors:  Ozlem Ozbagcivan; Sevgi Akarsu; Fatma Semiz; Emel Fetil
Journal:  Clin Oral Investig       Date:  2019-05-25       Impact factor: 3.573

2.  Induction of High Endothelial Venule-like Vessels in Oral and Cutaneous Lichen Planus: A Comparative Study.

Authors:  Hisato Yoshida; Yoshiaki Imamura; Hitoshi Yoshimura; Motohiro Kobayashi
Journal:  J Histochem Cytochem       Date:  2020-05       Impact factor: 2.479

3.  Elevated Granulysin Expression in Cytotoxic Lymphocytes from the Blood and Lesions of Patients with Lichen Planus.

Authors:  Marijana Vičić; Ines Brajac; Marija Kaštelan; Vlatka Sotošek; Larisa Prpić Massari
Journal:  Acta Derm Venereol       Date:  2021-07-13       Impact factor: 3.875

Review 4.  Adverse Immunologically Mediated Oral Mucosal Reactions to Systemic Medication: Lichenoid Tissue Reaction/Interface Dermatitis-Stomatitis, Autoimmune Vesiculobullous Disease, and IgE-Dependent and Immune Complex Reactions.

Authors:  R A G Khammissa; R Chandran; A Masilana; J Lemmer; L Feller
Journal:  J Immunol Res       Date:  2018-06-10       Impact factor: 4.818

5.  Down-regulation of miRNA-27b-3p suppresses keratinocytes apoptosis in oral lichen planus.

Authors:  Junjun Chen; Yufeng Wang; Guanhuan Du; Wenyi Zhang; Tianyi Cao; Linjun Shi; Yanni Wang; Jun Mi; Guoyao Tang
Journal:  J Cell Mol Med       Date:  2019-04-11       Impact factor: 5.310

6.  Intralesional and peripheral plasma of oral lichenoid reactions exhibit different cytokine profiles: A preliminary study.

Authors:  Kai Sun; Yi-Wen Deng; Jun Chen; Guan-Huan Du; Chencheng Song; Junjun Chen; Lei Pan; Xiaozhe Han; Yu-Feng Wang; Guo-Yao Tang
Journal:  J Dent Sci       Date:  2021-04-27       Impact factor: 2.080

7.  Assessment of bax and bcl-2 immunoexpression in patients with oral lichen planus and oral squamous cell carcinoma.

Authors:  Shima Nafarzadeh; Sina Jafari; Ali Bijani
Journal:  Int J Mol Cell Med       Date:  2013

8.  Immunoexpression of interleukin-22 and interleukin-23 in oral and cutaneous lichen planus lesions: a preliminary study.

Authors:  Jun Chen; Jinqiu Feng; Xiangdong Chen; Hui Xu; Zengtong Zhou; Xuemin Shen; Zhexuan Bao; Wei Liu; Zhengyu Shen
Journal:  Mediators Inflamm       Date:  2013-11-26       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.